Summary of significant accounting policies - Additional Information (Detail)		1 Months Ended		12 Months Ended
	Aug. 19, 2024 shares	Jun. 30, 2024	Mar. 31, 2024 USD ($)	Dec. 31, 2024 USD ($) Segment shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)
Financing Sources [Line Items]
Changes in fair value of common warrants reclassification adjustments					$ 2,200,000
Re-measurement loss				$ 3,400	45,700
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]				Chairman, President And Chief Executive Officer [Member]
Cash equivalent qualification, description				The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents.
Restricted cash				$ 110,000	70,000
Credit-related losses recognized				0
Impairment of right of use assets					724,000
Impairment of long lived assets				0	0
Dividends, common stock, cash				$ 0
Expected dividend yield				0.00%
Percentage of expected average remaining working lives of employees				10.00%
Reduction to R&D expenses				$ 2,800,000	$ 1,600,000
Stockholders' Equity, Reverse Stock Split	1-for-25
Common Stock, Shares, Outstanding | shares	79,900,000			3,864,436	3,003,855
Reduction in number of outstanding shares due to Reverse Stock Split | shares	3,300,000
Number of fractional shares issued in connection with reverse stock split | shares	0
Stockholders [Member]
Financing Sources [Line Items]
Stockholders' Equity, Reverse Stock Split		1-for-5 to 1-for-30
Board of Directors [Member]
Financing Sources [Line Items]
Stockholders' Equity, Reverse Stock Split		1-for-25
ABC Company
Financing Sources [Line Items]
Number of reportable segments | Segment				1
Grant by the National Institutes of Health (NIH) for Research to Target Coronaviruses
Financing Sources [Line Items]
Government grants / contract awarded				$ 1,500,000	$ 1,400,000	$ 1,100,000
Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]				Research and Development Expense	Research and Development Expense	Research and Development Expense
Grant by the National Institute of Allergies and Infectious Diseases (NIAID) for Research to Target Coronaviruses
Financing Sources [Line Items]
Government grants / contract awarded			$ 1,300,000	$ 9,800,000	$ 8,500,000
Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]			Research and Development Expense		Research and Development Expense
Government contract, duration				2026 years
General and Administrative (G&A) Expenses
Financing Sources [Line Items]
Impairment of right of use assets					$ 700,000